Drug Trial Radar · NCT00184574
Comparison of Biphasic Insulin Aspart 70/30, 50/50, and 30/70 in Subjects With Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: Jan 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
603
Actual
Start
Apr 2005
Primary completion
Mar 2006
Study completion Mar 2006
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Sep 16, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted in Europe. This trial aims for a comparison of the effect on glycemic control in subjects with type 2 diabetes of three different premixed insulin analogues given in combination with an oral anti-diabetic drug.
Conditions
- Diabetes
- Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspartDrug
metforminDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- HbA1cTime frame: after 36 weeks
Locations
108 sites in 18 countries. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Bregenz, Austria
Novo Nordisk Investigational Site
Feldkirch, Austria
Novo Nordisk Investigational Site
Graz, Austria
Novo Nordisk Investigational Site
Salzburg, Austria
Novo Nordisk Investigational Site
Vienna, Austria
Novo Nordisk Investigational Site
Bonheiden, Belgium
Novo Nordisk Investigational Site
Brussels, Belgium
Novo Nordisk Investigational Site
Genk, Belgium
Novo Nordisk Investigational Site
Ghent, Belgium
Novo Nordisk Investigational Site
Liège, Belgium
Novo Nordisk Investigational Site
Pleven, Bulgaria
Novo Nordisk Investigational Site
Sofia, Bulgaria
Novo Nordisk Investigational Site
Brno, Czechia
Novo Nordisk Investigational Site
Hradec Králové, Czechia
Novo Nordisk Investigational Site
Prague, Czechia
Novo Nordisk Investigational Site
Århus C, Denmark
Novo Nordisk Investigational Site
Køge, Denmark
Novo Nordisk Investigational Site
Odense, Denmark
Novo Nordisk Investigational Site
Antibes, France
Novo Nordisk Investigational Site
Boulogne-Billancourt, France
Novo Nordisk Investigational Site
Brest, France
Novo Nordisk Investigational Site
La Rochelle, France
Novo Nordisk Investigational Site
Le Chesnay, France
Novo Nordisk Investigational Site
Lille, France
Novo Nordisk Investigational Site
Metz, France
Novo Nordisk Investigational Site
Mougins, France
Novo Nordisk Investigational Site
Narbonne, France
Novo Nordisk Investigational Site
Nevers, France
Novo Nordisk Investigational Site
Perpignan, France
Novo Nordisk Investigational Site
Bad Heilbrunn, Germany
Novo Nordisk Investigational Site
Beckum, Germany
Novo Nordisk Investigational Site
Berlin, Germany
Novo Nordisk Investigational Site
Dormagen, Germany
Novo Nordisk Investigational Site
Dresden, Germany
Novo Nordisk Investigational Site
Duisburg, Germany
Novo Nordisk Investigational Site
Genthin, Germany
Novo Nordisk Investigational Site
Kippenheim, Germany
Novo Nordisk Investigational Site
München, Germany
Novo Nordisk Investigational Site
Pohlheim, Germany
Novo Nordisk Investigational Site
Saarbrücken, Germany
Showing 40 of 108 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.